Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8388394 | 0.87 | GHSR (0.57) | GHSRFFAR1FFAR4MAPTGAA | |
| SCHEMBL8756421 | 0.87 | GHSR (0.57) | GHSRFFAR1FFAR4MAPTGAA | |
| SCHEMBL8094483 | 0.83 | FFAR1 (0.68) | GHSRALDH1A1FFAR1FFAR4MAPT | |
| SCHEMBL11508663 | 0.83 | MAPT (0.64) | MAPT | |
| SCHEMBL11328551 | 0.83 | MAPT (0.64) | MAPT | |
| SCHEMBL3682494 | 0.83 | MAPT (0.64) | MAPT | |
| SCHEMBL11324887 | 0.83 | MAPT (0.64) | MAPT | |
| SCHEMBL29183022 | 0.83 | MAPT (0.64) | MAPT | |
| SCHEMBL11331977 | 0.83 | MAPT (0.64) | MAPT | |
| SCHEMBL3678588 | 0.83 | MAPT (0.64) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3438091-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | GHSR 6/4885CA12 4329/4885CA1 3303/4885 |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | GHSR 6/4885CA12 4329/4885CA1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.